Lifeloc Reports Third Quarter 2022 Results

Rhea-AI Summary

Lifeloc Technologies (LCTC) reported Q3 2022 financial results, revealing a net revenue of $2.032 million and a net loss of $(87) thousand, or $(0.04) per diluted share, compared to a profit of $523 thousand in Q3 2021. The overall nine-month revenue reached $6.373 million but incurred a loss of $(433) thousand, influenced by increased R&D investments and supply chain disruptions. Despite challenges, the launch of L-series devices is showing strong sales growth, and the company is advancing its SpinDx technology for rapid drug detection.

Positive

• Q3 2022 revenue increased by 8% year-over-year to $2.032 million.
• Strong sales growth from the new LX9 and LT7 devices.
• Progress on SpinDx technology for rapid drug detection with promising test results.

Negative

• Net loss for Q3 2022 was $(87) thousand, a decline from a profit of $523 thousand in Q3 2021.
• Incurred a net loss of $(433) thousand over nine months due to high R&D expenses and supply chain issues.
• Cancelled the planned spinoff of R.A.D.A.R. technology due to delays with SEC registration.

WHEAT RIDGE, CO / ACCESSWIRE / November 10, 2022 / Lifeloc Technologies, Inc. (OTC PINK:LCTC), a global leader in the development and manufacturing of breath alcohol and drug testing devices, has announced financial results for the third quarter ended September 30, 2022.

Third Quarter Financial Highlights

Lifeloc posted quarterly net revenue of $2.032 million in the third quarter of 2022, resulting in a quarterly net loss of $(87) thousand, or $(0.04) per diluted share. These results compare to net revenue of $1.887 million and quarterly net profit of $523 thousand, or $0.21 per diluted share in the third quarter of 2021. The income for the third quarter of 2021 includes the benefit from the forgiveness of the second round SBA Paycheck Protection Program (PPP) loan of $471 thousand. Revenue for the quarter increased 8% versus the third quarter last year, as demand continued to recover from the impact of the COVID-19 global pandemic and the government ordered shutdowns. Nine-month net revenue of $6.373 million and a net loss of $(433) thousand, or $(0.18) per diluted share, compared to net revenue of $5.427 million and a net profit of $816 thousand, or $0.33 per diluted share, for the same nine months of 2021. The income for the first nine months of 2021 includes the benefit from the forgiveness of both rounds of the SBA Paycheck Protection Program (PPP) loan of $936 thousand.

Increasing research and development investment as well as supply chain disruption contributed to the net loss in this quarter despite increased revenue. Supply chain delays have added some costs, and component inflation has added more. The company implemented a broad price increase during the second quarter in response to rising costs.

New platform LX9 and LT7 devices are producing strong sales growth. The L-series devices feature a high-resolution color display with a highly customizable user interface. Their features and performance have driven penetration by meeting previously unaddressable market needs, such as wider temperature ranges and fast customization that incorporates local languages. Based on our experience to date, we expect that most L-series sales will be incremental to FC-series devices rather than displacing FC sales. The L-series devices are meeting the requirements of the most modern registration standards, such as SAI's (Standards Australia International) latest AS 3547:2019 standards for Breath Alcohol Detectors.

We believe our most important goal and best opportunity remains the convergence of the global need for rapid detection of drugs of abuse with Lifeloc's proven capability to build easy-to-use portable testing equipment. We are focusing our research and development efforts on leveraging the SpinDx™ technology platform, sometimes referred to as "Lab on a Disk," to develop a series of devices and tests that can be used at roadside, emergency rooms, forensic labs and in workplace testing to get a rapid and quantitative measure for a panel of drugs of abuse, beginning with a device that allows for detection of delta-9-THC (the major intoxicating component of the cannabis plant) from a test subject's saliva. Testing has commenced to validate the SpinDx technology against the definitive standard liquid chromatography-mass spectroscopy (LCMS) measurement utilizing human samples. The human saliva SpinDx results are showing good correlation to the LCMS data. We are also developing a device based on our recently updated LX9 breathalyzer that, when coupled with the SpinDx technology, will be our marijuana breathalyzer system. In anticipation of possible SpinDx supply chain delays, we've already begun purchasing small quantities of components ahead of the initial production builds.

Our R.A.D.A.R.® 200 device has been introduced to the market, and the market feedback is that the device needs a few additional specific upgrades to gain widespread acceptance. The R.A.D.A.R. device promises to address a critical and valuable market need for self-administered alcohol monitoring. Lifeloc had formed a subsidiary, Probation Tracker Inc. (PTI), in preparation for a spinoff of the R.A.D.A.R. technology into a new entity devoted to engaging in the required additional developmental upgrades. Anticipating delays with the SEC on the registration of the PTI shares, we withdrew the registration, cancelled the planned spinoff and instead have engaged a consultant to outsource the remaining R.A.D.A.R. development. We have chosen this outsourcing route so that our internal research and development team can keep its primary focus on SpinDx commercialization.

"We have overcome a number of challenges over the last few years from pandemic and supply chain delays to labor tightness and inflation," commented Dr. Wayne Willkomm, President and CEO. "We are well positioned for the future, with the new L-series devices opening new opportunities and resulting in a growing revenue contribution as well as the product pipeline built on the SpinDx product platform. We expect research and development expenses to remain high in this push to complete the first of many products on the SpinDx platform, but we are choosing to prioritize substantial value creation over short-term profitability. We are excited to see positive results from the human samples in the SpinDx testing and look forward to getting these products released."

About Lifeloc Technologies

Lifeloc Technologies, Inc. (OTC: LCTC) is a trusted U.S. manufacturer of evidential breath alcohol testers and related training and supplies for Workplace, Law Enforcement, Corrections and International customers. Lifeloc stock trades over-the-counter under the symbol LCTC. We are a fully reporting Company with our SEC filings available on our web site, www.lifeloc.com/investor.

Forward Looking Statements

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which involve substantial risks and uncertainties that may cause actual results to differ materially from those indicated by the forward-looking statements. All forward-looking statements expressed or implied in this press release, including statements about our strategies, performance, expectations about new and existing products, market demand, economic conditions, acceptance of new and existing products, technologies and opportunities, market size and growth, and return on investments in products and market, are based on information available to us on the date of this document, and we assume no obligation to update such forward-looking statements. Investors are strongly encouraged to review the section titled "Risk Factors" in our SEC filings.

R.A.D.A.R.® is a registered trademark of Lifeloc Technologies, Inc.

SpinDx™ is a trademark of Sandia Corporation.

Amy Evans
Lifeloc Technologies, Inc.
http://www.lifeloc.com
(303) 431-9500

LIFELOC TECHNOLOGIES, INC.
Condensed Balance Sheets

	ASSETS
		September 30, 2022				December 31, 2021
CURRENT ASSETS:		(Unaudited)
Cash		$	2,124,531			$	2,571,668
Accounts receivable, net			658,322				562,092
Inventories, net			2,694,957				2,668,789
Prepaid expenses and other			115,938				56,897
Total current assets			5,593,748				5,859,446
PROPERTY AND EQUIPMENT, at cost:
Land			317,932				317,932
Building			1,928,795				1,928,795
Real-time Alcohol Detection And Recognition equipment and software			569,448				569,448
Production equipment, software and space modifications			1,149,855				958,785
Training courses			432,375				432,375
Office equipment, software and space modifications			216,618				216,618
Sales and marketing equipment and space modifications			226,356				226,356
Research and development equipment, software and space modifications			467,485				456,685
Less accumulated depreciation			(2,898,763	)			(2,518,966	)
Total property and equipment, net			2,410,101				2,588,028
OTHER ASSETS:
Patents, net			80,591				134,428
Deposits and other			500				163,480
Deferred taxes			345,228				204,449
Total other assets			426,319				502,357
Total assets		$	8,430,168			$	8,949,831
	LIABILITIES AND STOCKHOLDERS' EQUITY
CURRENT LIABILITIES:
Accounts payable		$	442,855			$	445,985
Term loan payable, current portion			49,645				48,513
Customer deposits			180,560				170,952
Accrued expenses			234,613				298,530
Deferred revenue, current portion			58,173				71,604
Reserve for warranty expense			46,500				46,500
Total current liabilities			1,012,346				1,082,084
TERM LOAN PAYABLE, net of current portion and
debt issuance costs			1,231,790				1,267,551
DEFERRED REVENUE, net of current portion			8,074				6,430
Total liabilities			2,252,210				2,356,065
COMMITMENTS AND CONTINGENCIES
STOCKHOLDERS' EQUITY:
Common stock, no par value; 50,000,000 shares
authorized, 2,454,116 shares outstanding			4,668,014				4,650,812
Retained earnings			1,509,944				1,942,954
Total stockholders' equity			6,177,958				6,593,766
Total liabilities and stockholders' equity		$	8,430,168			$	8,949,831

LIFELOC TECHNOLOGIES, INC.
Condensed Statements of Income (Unaudited)

		Three Months Ended September 30,
REVENUES:		2022				2021
Product sales		$	6,264,222			$	5,304,800
Royalties			40,437				56,157
Rental income			67,867				65,710
Total			6,372,526				5,426,667
COST OF SALES			4,099,087				3,063,321
GROSS PROFIT			2,273,439				2,363,346
OPERATING EXPENSES:
Research and development			1,056,026				873,498
Sales and marketing			821,821				751,266
General and administrative			943,060				852,998
Total			2,820,907				2,477,762
OPERATING INCOME (LOSS)			(547,468	)			(114,416	)
OTHER INCOME (EXPENSE):
Forgiveness of Paycheck Protection loan			-				936,444
Interest income			6,130				2,659
Interest expense			(32,451	)			(40,629	)
Total			(26,321	)			898,474
NET INCOME BEFORE PROVISION FOR TAXES			(573,789	)			784,058
BENEFIT FROM (PROVISION FOR) FEDERAL AND STATE INCOME TAXES			140,779				32,361
NET INCOME		$	(433,010	)		$	816,419
NET INCOME PER SHARE, BASIC		$	(0.18	)		$	0.33
NET INCOME PER SHARE, DILUTED		$	(0.18	)		$	0.33
WEIGHTED AVERAGE SHARES, BASIC			2,454,116				2,454,116
WEIGHTED AVERAGE SHARES, DILUTED			2,454,116				2,501,034

LIFELOC TECHNOLOGIES, INC.
Condensed Statements of Income (Unaudited)

		Nine Months Ended September 30,
REVENUES:		2022				2021
Product sales		$	6,264,222			$	5,304,800
Royalties			40,437				56,157
Rental income			67,867				65,710
Total			6,372,526				5,426,667
COST OF SALES			4,099,087				3,063,321
GROSS PROFIT			2,273,439				2,363,346
OPERATING EXPENSES:
Research and development			1,056,026				873,498
Sales and marketing			821,821				751,266
General and administrative			943,060				852,998
Total			2,820,907				2,477,762
OPERATING INCOME (LOSS)			(547,468	)			(114,416	)
OTHER INCOME (EXPENSE):
Forgiveness of Paycheck Protection loan			-				936,444
Interest income			6,130				2,659
Interest expense			(32,451	)			(40,629	)
Total			(26,321	)			898,474
NET INCOME (LOSS) BEFORE PROVISION FOR TAXES			(573,789	)			784,058
BENEFIT FROM (PROVISION FOR) FEDERAL AND STATE INCOME TAXES			140,779				32,361
NET INCOME (LOSS)		$	(433,010	)		$	816,419
NET INCOME (LOSS) PER SHARE, BASIC		$	(0.18	)		$	0.33
NET INCOME (LOSS) PER SHARE, DILUTED		$	(0.18	)		$	0.33
WEIGHTED AVERAGE SHARES, BASIC			2,454,116				2,454,116
WEIGHTED AVERAGE SHARES, DILUTED			2,454,116				2,493,492

Lifeloc Technologies, Inc.
Condensed Statements of Stockholders' Equity (Unaudited)

		Three Months Ended September 30,								Nine Months Ended September 30,
		2022				2021				2022				2021
Total stockholders' equity, beginning balances		$	6,264,930			$	6,211,558			$	6,593,766			$	5,900,642
Common stock (no shares issued during periods):
Beginning balances			4,668,014				4,650,812				4,650,812				4,633,655
Stock based compensation expense related
to stock options			-				-				17,202				17,157
Ending balances			4,668,014				4,650,812				4,668,014				4,650,812
Retained earnings:
Beginning balances			1,596,916				1,560,746				1,942,954				1,266,987
Net income (loss)			(86,972	)			522,660				(433,010	)			816,419
Ending balances			1,509,944				2,083,406				1,509,944				2,083,406
Total stockholders' equity, ending balances		$	6,177,958			$	6,734,218			$	6,177,958			$	6,734,218

LIFELOC TECHNOLOGIES, INC.
Condensed Statements of Cash Flows (Unaudited)

		Nine Months Ended September 30,
CASH FLOWS FROM OPERATING ACTIVITIES:		2022				2021
Net income (loss)		$	(433,010	)		$	816,419
Adjustments to reconcile net income to net cash
provided from (used in) operating activities-
Forgiveness of Paycheck Protection loans			-				(936,444	)
Depreciation and amortization			438,549				206,222
Provision for doubtful accounts, net change			-				(49,000	)
Provision for inventory obsolescence, net change			154,367				(5,000	)
Deferred taxes, net change			(140,779	)			12,927
Reserve for warranty expense, net change			-				-
Stock based compensation expense related to
stock options			17,202				17,157
Changes in operating assets and liabilities-
Accounts receivable			(96,230	)			(27,465	)
Inventories			(180,535	)			(82,991	)
Income taxes receivable			-				175,369
Prepaid expenses and other			(59,041	)			(11,430	)
Deposits and other			162,980				1,318
Accounts payable			(3,130	)			(103,279	)
Customer deposits			9,608				3,080
Accrued expenses			(63,917	)			(71,780	)
Deferred revenue			(11,787	)			6,458
Net cash provided from (used in)
operating activities			(205,723	)			(48,439	)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of property and equipment			(201,870	)			(64,254	)
Patent filing expense			(1,687	)			(661	)
Net cash (used in) investing activities			(203,557	)			(64,915	)
CASH FLOWS FROM FINANCING ACTIVITIES:
Principal payments made on term loan			(37,857	)			(1,328,625	)
Proceeds from refinancing term loan			-				1,350,000
Cost of refinancing term loan			-				(18,156	)
Proceeds from Paycheck Protection loan (round 2)			-				471,347
Net cash provided from (used in) financing
activities			(37,857	)			474,566
NET INCREASE (DECREASE) IN CASH			(447,137	)			361,212
CASH, BEGINNING OF PERIOD			2,571,668				2,195,070
CASH, END OF PERIOD		$	2,124,531			$	2,556,282
SUPPLEMENTAL INFORMATION:
Cash paid for interest		$	29,223			$	39,815
Cash paid for income tax		$	-			$	-

SOURCE: Lifeloc Technologies, Inc.

View source version on accesswire.com:
https://www.accesswire.com/725092/Lifeloc-Reports-Third-Quarter-2022-Results

FAQ

What were the Q3 2022 results for Lifeloc Technologies (LCTC)?

Lifeloc Technologies reported Q3 2022 net revenue of $2.032 million, with a net loss of $(87) thousand.

How did Lifeloc's Q3 2022 revenue compare to Q3 2021?

Q3 2022 revenue of $2.032 million represents an 8% increase compared to $1.887 million in Q3 2021.

What are the main factors affecting LCTC's financial performance in Q3 2022?

The financial performance was impacted by increased research and development investment, supply chain disruptions, and inflation.

What is the SpinDx technology being developed by Lifeloc Technologies?

SpinDx technology aims to provide rapid detection of drugs of abuse, starting with delta-9-THC detection from saliva.

What changes occurred regarding the R.A.D.A.R. device and its spinoff?

The planned spinoff of the R.A.D.A.R. technology was cancelled due to SEC registration delays, and development is now outsourced.